研究单位：[1]Hangzhou Jiayin Biotech Ltd[2]Beijing Hospital,Peking,Beijing,China,100000[3]Beijing Tongren Hospital,Cmu,Peking,Beijing,China,100000[4]Peking University People'S Hospital,Peking,Beijing,China,100000[5]The Southwest Hospital of Amu,Chongqing,Chongqing,China[6]Central theater General Hospital,Wuhai,Hubei,China[7]Jiangsu Provinve Hospital,Nanjing,Jiangsu,China[8]The Second Affiliated Hospital Zhejiang University School of Medicine,Hangzhou,Zhejiang,China[9]Eye Hospital,WMU,Wenzhou,Zhejiang,China
In neovascular (wet) age-related macular degeneration (wAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with wAMD.
